Journal Browser

Go Edit a Special Issue

Archive

Special Issue Title:

Novel Medications and Treatments of Acute Phase Asthma Attacks

Deadline for manuscript submissions: 03 November 2021

Print Special Issue Flyer (7)

Special Issue Editor

  • Guest Editor

    Dr. Hassan MotamedE-MailWebsite

    Associate Professor of Emergency Medicine, Department of Emergency Medicine, School of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran.

    Interests: Acute phase asthma novel managements, Diagnostic biomarkers, Sedation and analgesia, Ketamine novel applications

Special Issue Information

Asthma as a chronic airway disease manifests with recurrent reversible airway obstruction. According to the Centers for Disease Control and Prevention (CDC), 1 out of 13 individuals experiences asthma, A number of more than 25 million Americans. A percentage of 7.7% of adults and 8.4% of children. Asthma is identified as a prominent etiology for missed workdays. It is responsible for annually 1.5 million ED visits and up to 500,000 admissions each year and a mortality for over 3,300 Americans per year. 

 Asthma is the culprit of significant number of missing school and work days due to the disease restrictions. Asthma is an important chronic disease which imposes a huge financial pressure on medical health services. Acute attacks and referral to Emergency Department is a challenge. Many Environmental Factors influences asthma in addition to its hereditary basis. Many cross-sectional studies have confirmed increases in the incidence and prevalence of asthma over the past 2 to 3 decades. Almost 25% of annual Emergency Departments visits are related to asthma. Asthma; specially in acute setting medical management is a research attraction. 

Novel therapeutic strategy results are challenging and complex. A lot of new treatment are under investigation. Traditional standard medications in the disease acute setting consist of Oxygen administration, B2 adrenergic agonists, anticholinergics and corticosteroids depends on the severity of the attack. Many research projects are designed and are published or are in process for application of novel medicine such as nebulized heparin, nebulized ketamine, nebulized lidocaine, nebulized low molecular weight heparin (LMWH), Nebulized lidocaine, leukotriene inhibitors, nebulized dexmedetomidine, nebulized ketamine, application of heliox, nebulized tacrolimus, nebulized magnesium, alprostadil IV administration, Intravenous B-type Natriuretic Peptide IV administration in acute phase management of acute asthma attack to serve a better fast improvement of the acute disease. There are significant controversies in the field of new introduced medications, suggesting for acute asthma treatment and a lot of ambivalences that should be answered. This is a long way to clarify the costs and benefits of the different under investigation drugs and the conflicts in the research results. More trials are needed to clarify a lot of questions to open more windows to the asthma acute attack treatment specially for the Emergency Departments. We hope that multiple clinical and experimental scientific trials improve our science of acute phase asthma disease management in Emergency Departments.  

Keywords

Asthma, Acute phase management, Novel medicine

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Signa Viate is an international peer-reviewed open access journal published by MRE Press. As of January 2021, Signa Vitae will change to a bimonthly journal. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Plan Papers (0 papers)

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences